Curisium brings a new approach to outcomes-based healthcare contracts with blockchain
At the core of the Curisium offering is an end-to-end solution centered around patient-level data and focused on value-based care.
From patient populations to individual patients
While other outcomes-based healthcare contract platforms only address patient population data, Curisium addresses individual patient data. The company argues that their move to more granular, patient-level data gives their platform superior flexibility. When patient population data is needed, it can be easily aggregated from the patient-level data.
From event data to patient-state data
The Curisium team also maintains that their approach departs from another common tenant of legacy platforms: the focus on event-based data. According to Curisium, the focus among legacy systems on healthcare events generates sparse datasets that lead to relatively unreliable, opaque automated contracts. By contrast, Curisium’s health state-based approach leads to reliable, rich datasets well-suited for automated contracts and new insights.
The issue of trust
The blockchain-based Curisium platform addresses the issue of trust directly. Outcomes-based healthcare data is generally locked away in separate silos owned by separate payers, providers and life sciences organizations. Unsurprisingly, previous outcomes-based contract platforms have struggled with the delicate task of convincing the various data-silo owners to trust eachother enough to share and aggregate their highly sensitive and heavily regulated data. However, according to Curisium, their platform provides “cryptographic guarantees” that reassure payers, providers and life science organizations that their shared data will remain secure. Furthermore, Curisium’s blockchain-based platform inherently provides an immutable record of all transactions, creating a built-in audit trail that facilitates verification and dispute resolution.
According to the Curisium team, legacy systems have had difficulty efficiently processing outcomes-based contracts. However, the Curisium platform has payment processing built in at a foundational level, leading to inherently efficient and affordable payment automation.
The Curisium team is led by co-founders Peter Kim, CEO, and Francis Lam, CTO, both formerly of Aetion, a provider of evidential data supporting value-based healthcare solutions.
Kim is the former VP of Engineering at Aetion, where he led the engineering and product teams to build their leading analytics platform running on “real-world evidence (RWE).” As co-founder of Curisium, Kim saw an opportunity to address the “costly logistics, lack of trust, and difficulty verifying patient-level outcomes” faced by healthcare and life sciences organizations limited by legacy payment platforms.
Lam was VP of Data Science at Aetion, where he “pioneered the use of patient states” to greatly increase platform efficiency.
Five firms are contributing to Curisium’s $3.5M seed investment round: New Enterprise Associates, Shuttle Fund, Flare Capital Partners, Green Bay Ventures and Sanofi Ventures. Two investors will join the Curisium’s Board of Directors: Mohamad Makhzoumi of New Enterprise Associates, and Bill Geary of Flare Capital. In Curisium’s press release, Geary argues that Curisium “has the potential to rapidly accelerate the breadth and depth of innovative contracting arrangements” by virtue of its patient-level outcome verification and automated-payment capabilities.